UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

The New England journal of medicine, 2009-11, Vol.361 (22), p.2113-2122

2009

Volltextzugriff (PDF)

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

Pharmacotherapy, 2010-08, Vol.30 (8), p.787-796

2010

Volltextzugriff (PDF)

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

Journal of the American College of Cardiology, 2010-06, Vol.55 (24), p.2721-2726

2010

Volltextzugriff (PDF)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Journal of personalized medicine, 2013-06, Vol.3 (2), p.111-123

2013

Volltextzugriff (PDF)

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

European heart journal, 2012-12, Vol.33 (23), p.2939-2945

2012

Volltextzugriff (PDF)

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Journal of the American College of Cardiology, 2010-06, Vol.55 (24), p.2721-2726

2010

Volltextzugriff (PDF)

Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials

Pharmacotherapy, 2014-05, Vol.34 (5), p.452-463

2014

Volltextzugriff (PDF)

On Pharmacogenomics in Pharmacy Benefit Management

Pharmacotherapy, 2012-02, Vol.32 (2), p.103-111

2012

Volltextzugriff (PDF)

Flushing and the HDL-C response to extended-release niacin

Journal of clinical lipidology, 2008-08, Vol.2 (4), p.285-288

2008

Volltextzugriff (PDF)

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Clinical therapeutics, 2007, Vol.29 (1), p.196-209

2007

Volltextzugriff (PDF)

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Current medical research and opinion, 2007-03, Vol.23 (3), p.553-563

2007

Volltextzugriff (PDF)

Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

Journal of clinical lipidology, 2008-10, Vol.2 (5), p.343-353

2008

Volltextzugriff (PDF)

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

Journal of the American College of Cardiology, 2012-03, Vol.59 (13), p.E1848-E1848

2012

Volltextzugriff (PDF)

Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients

The Annals of pharmacotherapy, 2004-07, Vol.38 (7-8), p.1136

2004

Volltextzugriff (PDF)

Paradoxical progression of atherosclerosis related to low-density tipoprotein reduction and exposure to ezetimibe

European heart journal, 2012, Vol.33 (23), p.2939-2945

2012

Volltextzugriff (PDF)

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y^sub 12^ inhibition: Results of the randomized DOSAPI study

European journal of clinical pharmacology, 2014-09, Vol.70 (9), p.1049

2014

Volltextzugriff (PDF)

Abstract 16675: Assessment of Initial U.S. Dabigatran Utilization and Short-Term Persistence

Circulation (New York, N.Y.), 2011-11, Vol.124 (suppl_21)

2011

Volltextzugriff (PDF)

Abstract P241: One-Year Cost-Effectiveness of Cytochrome P450 2C19 Genotype-Guided Antiplatelet Therapy in Patients With Acute Coronary Syndromes

Circulation Cardiovascular quality and outcomes, 2011-11, Vol.4 (suppl_1)

2011

Volltextzugriff (PDF)

Niacin Compared with Ezetimibe

The New England journal of medicine, 2010-03, Vol.362 (11), p.1046-1048

2010

Volltextzugriff (PDF)

Platelet Inhibition with Cangrelor

The New England journal of medicine, 2010-03, Vol.362 (11), p.1048-1049

2010

Volltextzugriff (PDF)

Abstract P212: Benchmark Analysis of Genetic Testing Practice Patterns in a Real-World Population of Patients Receiving Clopidogrel or Prasugrel Therapy

Circulation Cardiovascular quality and outcomes, 2011-11, Vol.4 (suppl_2)

2011

Volltextzugriff (PDF)

Abstract 290: Statin Adherence in Males and Females, and the Impact of Knowledge of a Genetic Test: Results from the AKROBATS Trial

Circulation Cardiovascular quality and outcomes, 2012-04, Vol.5 (suppl_1)

2012

Volltextzugriff (PDF)

Arterial oxygen saturation in chronic congestive heart failure

The American journal of cardiology, 1994-01, Vol.73 (2), p.180-185

1994

Volltextzugriff (PDF)

Abstract 4162: Cardiovascular Event Reduction Associated with Achieving Optimal Values for Multiple Lipids

Circulation (New York, N.Y.), 2006-10, Vol.114 (suppl_18)

2006

Volltextzugriff (PDF)

820-6 Once-daily niacin extended-release is effective and safe for treatment of dyslipidemia associated with chronic kidney disease

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A487-A487

2004

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(55)
Berichte
(2)

Sprache

Englisch
(57)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information

Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)

Sigmoidal Maximal Effect Modeling of Low-Density Lipoprotein Cholesterol Concentration and Annual Incidence of Coronary Heart Disease Events in Secondary Prevention Trials

On Pharmacogenomics in Pharmacy Benefit Management

Flushing and the HDL-C response to extended-release niacin

Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?

Risk of cardiovascular events in patients at optimal values for combined lipid parameters

Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients

Paradoxical progression of atherosclerosis related to low-density tipoprotein reduction and exposure to ezetimibe

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y^sub 12^ inhibition: Results of the randomized DOSAPI study

Abstract 16675: Assessment of Initial U.S. Dabigatran Utilization and Short-Term Persistence

Abstract P241: One-Year Cost-Effectiveness of Cytochrome P450 2C19 Genotype-Guided Antiplatelet Therapy in Patients With Acute Coronary Syndromes

Niacin Compared with Ezetimibe

Platelet Inhibition with Cangrelor

Abstract P212: Benchmark Analysis of Genetic Testing Practice Patterns in a Real-World Population of Patients Receiving Clopidogrel or Prasugrel Therapy

Abstract 290: Statin Adherence in Males and Females, and the Impact of Knowledge of a Genetic Test: Results from the AKROBATS Trial

Arterial oxygen saturation in chronic congestive heart failure

Abstract 4162: Cardiovascular Event Reduction Associated with Achieving Optimal Values for Multiple Lipids

820-6 Once-daily niacin extended-release is effective and safe for treatment of dyslipidemia associated with chronic kidney disease

Aktive Filter

Suchergebnisse filtern